Modification of the environment is not the most efficient way to prevent type 1 diabetes

Diabetes Technology and Therapeutics

Volumn 2, Issue 4, 2000, Pages 609-616

  Abiru, N ^a   Yu, L ^a   Redondo, M ^a   Eisenbarth, G S ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; INSULIN; INSULIN ANTIBODY; T LYMPHOCYTE RECEPTOR;

CELL DESTRUCTION; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NOTE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIET; ENVIRONMENT; FEMALE; HUMANS; INSULIN ANTIBODIES; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED NOD; PEDIGREE; PREDIABETIC STATE; PREVALENCE; RISK FACTORS;

EID: 0034467475     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/15209150050502032     Document Type: Note

References (44)

1. Unraveling the genetics of insulin-dependent type 1A diabetes: The search must go on
2. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
3. Autoantigens IA-2 and GAD in type I (insulin-dependent) diabetes
4. Genetics of type 1 diabetes mellitus
5. Newborn screening for HLA markers associated with IDDM: Diabetes autoimmunity study in the young (DAISY)
6. Prediction of IDDM in the general population: Strategies based on combinations of autoantibody markers
7. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease
8. Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: Time trend analysis
9. Twin studies in insulin-dependent diabetes and other autoimmune diseases
10. Increased β-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse
11. Early expression of anti-insulin autoantibodies of man and the NOD mouse: Evidence for early determination of subsequent diabetes
12. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice
13. Autoimmune diabetes: The involvement of benign and malignant autoimmunity
14. + T cells
15. The Melbourne Pre-Diabetes Study: Prediction of type 1 diabetes mellitus using antibody and metabolic testing
16. Dual parameter model for prediction of type 1 diabetes mellitus
17. Defects in beta-cell function and insulin sensitivity in normoglycemic streptozotocin-treated baboons: A model of preclinical insulin-dependent diabetes
18. The world of insulin-dependent diabetes mellitus: What international epidemiologic studies reveal about the etiology and natural history of IDDM
19. Geographic variation in mortality among individuals with youth-onset diabetes mellitus across the world
20. Genetics of insulin-dependent diabetes mellitus
21. Gene defect behind APECED: A new clue to autoimmunity
22. Evidence for oligogenic inheritance of type 1A diabetes in a large Bedouin Arab family
23. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: Prospective twin study
24. Late progression to diabetes and evidence for chronic β-cell autoimmunity in identical twins of patients with type I diabetes
25. Lack of association between early exposure to cow's milk protein and β-cell autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY)
26. Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (DAISY)
27. Lack of association between early childhood immunizations and beta-cell autoimmunity
28. Transient antiislet autoantibodies: Infrequent occurrence and lack of association with "genetic" risk factors
29. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease-associated transglutaminase autoantibodies
30. Transglutaminase antibodies in children with a genetic risk for celiac disease
31. DRB1*04 and DQ alleles: Expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease
32. The NOD mouse model of type 1 diabetes: As good as it gets?
33. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals
34. Insulin immunization protects NOD mice from diabetes
35. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
36. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin
37. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes
38. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice
39. Administering glutamic acid decarboxylase to NOD mice prevents diabetes
40. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice
41. Protective and destructive effects of microbial infection in insulin-dependent diabetes mellitus
42. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various β-cell antigens
43. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice
44. Dual overlapping peptides recognized by insulin peptide B:9-23 reactive T cell receptor AV13S3 T cell clones of the NOD mouse